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BACKGROUND
Systemic glucocorticoids reduce the incidence of bronchopulmonary dysplasia 
among extremely preterm infants, but they may compromise brain development. 
The effects of inhaled glucocorticoids on outcomes in these infants are unclear.
METHODS
We randomly assigned 863 infants (gestational age, 23 weeks 0 days to 27 weeks 
6 days) to early (within 24 hours after birth) inhaled budesonide or placebo until 
they no longer required oxygen and positive-pressure support or until they reached 
a postmenstrual age of 32 weeks 0 days. The primary outcome was death or broncho-
pulmonary dysplasia, confirmed by means of standardized oxygen-saturation 
monitoring, at a postmenstrual age of 36 weeks.
RESULTS
A total of 175 of 437 infants assigned to budesonide for whom adequate data were 
available (40.0%), as compared with 194 of 419 infants assigned to placebo for 
whom adequate data were available (46.3%), died or had bronchopulmonary dys-
plasia (relative risk, stratified according to gestational age, 0.86; 95% confidence 
interval [CI], 0.75 to 1.00; P = 0.05). The incidence of bronchopulmonary dysplasia 
was 27.8% in the budesonide group versus 38.0% in the placebo group (relative risk, 
stratified according to gestational age, 0.74; 95% CI, 0.60 to 0.91; P = 0.004); death 
occurred in 16.9% and 13.6% of the patients, respectively (relative risk, stratified 
according to gestational age, 1.24; 95% CI, 0.91 to 1.69; P = 0.17). The proportion 
of infants who required surgical closure of a patent ductus arteriosus was lower 
in the budesonide group than in the placebo group (relative risk, stratified accord-
ing to gestational age, 0.55; 95% CI, 0.36 to 0.83; P = 0.004), as was the proportion 
of infants who required reintubation (relative risk, stratified according to gesta-
tional age, 0.58; 95% CI, 0.35 to 0.96; P = 0.03). Rates of other neonatal illnesses 
and adverse events were similar in the two groups.
CONCLUSIONS
Among extremely preterm infants, the incidence of bronchopulmonary dysplasia 
was lower among those who received early inhaled budesonide than among those 
who received placebo, but the advantage may have been gained at the expense of 
increased mortality. (Funded by the European Union and Chiesi Farmaceutici; 
ClinicalTrials.gov number, NCT01035190.)
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A bout one half of preterm infants (gestational age, <28 weeks) have bron-chopulmonary dysplasia,1,2 which is a ma-
jor cause of early death.1,3 Infants with broncho-
pulmonary dysplasia who survive have increased 
risks of neurodevelopmental impairment 4 and 
respiratory problems later in life.5,6
Bronchopulmonary dysplasia results from on-
going lung injury and simultaneous repair 7,8; 
inflammation related to chorioamnionitis, post-
natal infections, or iatrogenic causes (such as 
the use of ventilation or oxygen) contributes to 
lung fibrosis and arrested lung development.7,9 
Systemic glucocorticoids have been shown to 
reduce the incidence of bronchopulmonary dys-
plasia, but they may cause short-term and long-
term adverse effects, including intestinal perfo-
ration and cerebral palsy.10
A plausible alternative to systemic administra-
tion of glucocorticoids is delivery of glucocorti-
coids by inhalation.11 Unfortunately, most trials 
in which this method has been used have been 
small or did not initiate administration of gluco-
corticoids promptly after birth,12 which may be 
important since the pulmonary inflammatory 
response in preterm infants in whom broncho-
pulmonary dysplasia develops starts very early in 
life and may even appear prenatally.13-15 We there-
fore conducted a multinational, randomized trial 
to test the hypothesis that in preterm infants 
born before 28 weeks of gestation, inhaled 
budesonide administered within 24 hours after 
birth would decrease the incidence of broncho-
pulmonary dysplasia and death at 36 weeks of 
postmenstrual age.16
Me thods
Study Patients
Infants with a gestational age of 23 weeks 0 days 
to 27 weeks 6 days and a chronologic age of 12 
hours or less who required any form of positive-
pressure support were eligible. Figure 1 shows 
the reasons for exclusion.
Study Oversight
The trial was approved by the research ethics 
board at University Hospital, Tübingen, and at 
each of the participating centers. Appropriate 
regulatory approvals and written informed con-
sent from parents or guardians were obtained 
before randomization. All the authors vouch for 
the accuracy and completeness of the data and 
the fidelity of the report to the study protocol, 
which is available with the full text of this article 
at NEJM.org. Metered-dose inhalers containing 
the study drugs were supplied free of charge 
by the manufacturer, Chiesi Farmaceutici, and 
Trudell Medical International supplied spacers 
(AeroChamber mini) free of charge; these com-
panies had no role in the design or conduct of 
the trial, the analysis of the data, the reporting 
and interpretation of the results, or the writing 
of the manuscript.
Randomization
A computer-generated randomization scheme with 
a fixed block size of 8 was used to assign infants, 
in a 1:1 ratio, to a study group, with stratifica-
tion according to gestational age (23 weeks 0 days 
to 25 weeks 6 days vs. 26 weeks 0 days to 27 weeks 
6 days). The manufacturer of the study drug re-
ceived the sequence of study-drug assignments 
from a statistician at the coordinating center 
and prepared drug packages, each of which con-
tained eight sequentially numbered metered-
dose inhalers that were identical in appearance. 
Packages of coded inhalers containing the study 
drugs were delivered to each participating center 
to ensure concealment of randomization. Infants 
were considered to have been randomly assigned 
at the time of the first signing of a prescription 
for the study drug.
Study Design
To ensure that all the infants received the study 
drug within 24 hours after birth, eligible infants 
received the first dose within 12 hours after ran-
dom assignment. Study drugs were administered 
by means of a metered-dose inhaler connected 
to a spacer. This spacer, which had a capacity of 
110 ml, was filled with a sufficient amount of 
oxygen to keep the infant in the targeted oxygen-
saturation range. For infants receiving mechani-
cal ventilation, the spacer was inserted into the 
ventilator circuit close to the endotracheal tube. 
For infants receiving nasal respiratory support, 
the spacer was connected to a face mask.
The dose of budesonide was two puffs (200 μg 
per puff) administered every 12 hours in the first 
14 days of life and one puff administered every 
12 hours from day 15 until the last dose of the 
study drug had been administered. The placebo 
contained only hydrofluoroalkane propellant.
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Study drugs were administered until infants no 
longer needed supplemental oxygen and positive-
pressure support or reached a postmenstrual age 
of 32 weeks 0 days, regardless of ventilator sta-
tus. Attending physicians could withhold or de-
crease doses of study drugs at their discretion. 
To minimize contamination, the study protocol 
strongly discouraged the use of open-label in-
haled glucocorticoids. All other interventions 
were prescribed at the discretion of the local 
clinicians. No one involved in patient care or in 
the assessment and analysis of outcomes was 
aware of the individual study-group assignments 
before completion of the analysis.
Primary Outcome
The primary outcome was a composite of death 
or bronchopulmonary dysplasia at 36 weeks of 
postmenstrual age. Bronchopulmonary dyspla-
sia was defined as the requirement for positive-
pressure support, the requirement for supple-
mental oxygen at a fraction of inspired oxygen 
Figure 1. Eligibility, Randomization, and Follow-up.
In case of a multiple‑birth pregnancy, only one of the multiples (the second in birth order, when possible) was con‑
sidered eligible for the study, to prevent a correlated data problem.
863 Underwent randomization
1767 Were available
2233 Infants met inclusion criteria
Gestational age of 23 wk 0 days–27 wk 6 days
Chronologic age ≤12 hr
Any positive-pressure support
466 Were excluded
61 Were to receive only palliative care
27 Had dysmorphic features or congenital 
abnormalities likely to affect life expectancy
or neurologic development
12 Had known or strongly suspected cyanotic
heart disease
342 Were from a multiple-birth pregnancy, other
than the second infant in birth order
24 Met multiple exclusion criteria
904 Did not undergo randomization
423 Had parents who were not approached
480 Had parents who did not provide consent
1 Did not undergo randomization despite
provision of consent
441 Were assigned to budesonide group
438 Received assigned study drug
3 Did not receive assigned study drug
422 Were assigned to placebo group
422 Received assigned study drug
4 Had unknown outcome
because of withdrawal of 
consent or right to use data
3 Had unknown outcome
because of withdrawal of
consent or right to use data
437 Were followed to the first discharge home 419 Were followed to the first discharge home
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exceeding 0.30, or, in infants receiving low 
amounts of oxygen, an inability to maintain an 
oxygen-saturation value above 90% during a 
structured, short period of saturation monitor-
ing coupled with gradual weaning from oxygen 
to ambient air (the oxygen-reduction test).17
Secondary Outcomes
Prespecified secondary outcomes were the follow-
ing: death for any reason at 36 weeks of post-
menstrual age; bronchopulmonary dysplasia 
(defined in the same way as for the primary 
outcome) in survivors at 36 weeks of postmen-
strual age17; the duration of positive-pressure 
respiratory support or supplemental oxygen; ven-
triculomegaly with or without intraventricular 
hemorrhage18 (diagnosed on the basis of the 
worst finding on cranial ultrasonography per-
formed at or before 36 weeks of postmenstrual 
age); patent ductus arteriosus requiring drug 
treatment or surgery; and intestinal perforation 
or necrotizing enterocolitis (diagnosed during 
surgery, at autopsy, or by a finding of pneuma-
tosis intestinalis, hepatobiliary gas, or free intra-
peritoneal air on abdominal radiography).
Additional prespecified secondary outcomes 
were retinopathy of prematurity (stage 2 or high-
er according to the international classification19 
or requiring treatment), culture-proven infections 
(defined as episodes of sepsis or meningitis con-
firmed by blood or cerebrospinal fluid culture 
growing bacteria, fungi, or viruses), increases in 
weight and head circumference from birth to 
day 28, the length of hospitalization, a need for 
reintubation after the last dose of study drug 
had been administered, and the occurrence of 
oral candidiasis requiring treatment, hyperglyce-
mia requiring insulin treatment, or hypertension 
requiring treatment. The results of neurodevel-
opmental disability testing at 18 to 22 months of 
corrected age are not reported here.
Statistical Analysis
Assuming a rate of death or bronchopulmonary 
dysplasia of 50% in the placebo group, we calcu-
lated that 808 infants would have to be enrolled 
for the study to have 80% power (at a two-sided 
alpha level of 5%) to detect a 20% lower risk in 
the budesonide group. With an anticipated loss 
to follow-up, we aimed to recruit 850 infants.
We assessed the primary outcome by means 
of a Mantel–Haenszel chi-square test stratified 
according to gestational age (23 weeks 0 days to 
25 weeks 6 days vs. 26 weeks 0 days to 27 weeks 
6 days), at a two-sided alpha rate of 0.05. The 
analysis was performed on the basis of the inten-
tion-to-treat principle. We performed a second-
ary analysis using a logistic-regression model ad-
justed for gestational age, maternal age, family 
structure (single vs. two-parent family at the 
time of delivery), antenatal glucocorticoid use 
(yes vs. no), presence or absence of chorioamnio-
nitis (defined histologically), intubation status, 
birth weight (<750 g vs. ≥750 g), sex, multiple vs. 
singleton gestation, and caffeine use (yes vs. no). 
The final model was checked for colinearities 
and interactions and includes, besides therapy, 
only factors with P values of less than 0.05. For 
the primary outcome, we also conducted pre-
specified analyses in subgroups defined accord-
ing to intubation status, gestational age, and the 
presence or absence of chorioamnionitis.
Comparisons of secondary outcomes were 
performed with the use of stratified and non-
stratified Cochran–Mantel–Haenszel tests for di-
chotomous outcomes. Continuous outcomes were 
checked for normal distribution and analyzed 
with the use of Student’s t-test and analysis of 
variance, with posterior tests if they were normal-
ly distributed and Wilcoxon and Kruskal–Wallis 
tests with posterior tests if they were nonnormal-
ly distributed.20 Censored data were analyzed 
with the use of Kaplan–Meier estimates and the 
log-rank test. Hazard ratios were calculated with 
the use of Cox regression. Two-sided P values of 
less than 0.05 were considered to indicate statis-
tical significance. SAS software, version 9.2 (SAS 
Institute) was used for analyses.
An independent statistician conducted one 
planned interim analysis for efficacy after 50% of 
the infants had been enrolled; an external data 
and safety monitoring committee reviewed the 
analysis. A Haybittle–Peto stopping boundary was 
set at a P value of less than 0.001. The external 
data and safety monitoring committee reviewed 
safety data four times. After the last review, when 
patient enrollment had already been completed, 
the committee recommended that the study drugs 
be withheld because of a borderline significant 
between-group difference in the rate of death ac-
cording to the data available for review at that 
time. However, at the time of this recommenda-
tion, study drugs had already been discontinued 
in all patients according to the protocol.
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R esult s
Study Patients
A total of 863 infants at 40 study centers in nine 
countries underwent randomization from April 1, 
2010, to August 3, 2013 (Fig. 1). The study popu-
lation included 10 infants who were part of a 
multiple birth and who were not the second in 
birth order (in 9 cases, the second multiple had 
died prenatally, was not considered viable at birth, 
or died before randomization; in 1 case, both 
infants in a set of twins underwent randomiza-
tion by mistake). The outcome for 7 infants was 
unknown owing to withdrawal of consent or of 
the right to use the data, leaving 856 in the 
analysis population. The baseline characteristics 
of the infants and of the mothers were similar 
in the two groups (Table 1).
Cointerventions
Twelve infants, seven in the budesonide group 
(1.6%) and five in the placebo group (1.2%), re-
ceived at least one puff of open-label inhaled 
glucocorticoids before 32 weeks of postmen-
strual age, either because of an administrative 
error or intentionally. Clinicians administered 
systemic glucocorticoids, inhaled bronchodilators, 
intramuscular vitamin A, and methylxanthines 
similarly in the two groups, but they adminis-
tered diuretics more frequently in the placebo 
group (Table 2).
Primary Outcome
A total of 856 infants were evaluated for the pri-
mary outcome. Overall, 131 infants died before 
36 weeks of postmenstrual age, and 239 infants 
were classified as having bronchopulmonary 
dysplasia. In 52 of the infants with bronchopul-
monary dysplasia (21.8%), the diagnosis was 
based on the results of the oxygen-reduction test; 
this test was performed at 36 weeks 0 days±1 day 
in all but 3 infants (2 of whom underwent testing 
at 36 weeks 2 days and 1 of whom underwent 
testing at 36 weeks 3 days of postmenstrual age). 
The observed rate of death or bronchopulmo-
nary dysplasia was 40.0% (175 of 437 infants) in 
the budesonide group and 46.3% (194 of 419 in-
fants) in the placebo group (relative risk, stratified 
according to gestational age, 0.86; 95% confidence 
interval [CI], 0.75 to 1.00; P = 0.05) (Table 3).
In a secondary analysis that included adjust-
ment for other covariates, the odds ratio for the 
primary outcome in the budesonide group, as 
compared with the placebo group, was 0.71 
(95% CI, 0.53 to 0.97; P = 0.03). The treatment 
effect was not significantly influenced by intu-
bation status, gestational age, or the presence or 
Characteristic
Budesonide 
 Group 
(N = 437)
Placebo 
Group 
(N = 419)
Mothers
Age — yr 30.7±6.0 30.8±5.9
Race — no. (%)†
White 369 (84.4) 359 (85.7)
Black 36 (8.2) 30 (7.2)
Asian 8 (1.8) 7 (1.7)
Other or unknown 24 (5.5) 23 (5.5)
Use of antenatal glucocorticoids — no. (%) 388 (88.8) 383 (91.4)
Cesarean section — no. (%) 299 (68.4) 282 (67.3)
Chorioamnionitis — no. (%)
Antibiotics received 229 (52.4) 220 (52.5)
Histologic diagnosis 90 (20.6) 76 (18.1)
Educational level — no. (%)
High school or less 155 (35.5) 162 (38.7)
High‑school graduate 130 (29.7) 129 (30.8)
Some college or university 127 (29.1) 113 (27.0)
Unknown 25 (5.7) 15 (3.6)
Single‑parent family — no. (%) 39 (8.9) 39 (9.3)
Infants
Birth weight — g 798±193 803±189
Gestational age at birth — wk 26.1±1.3 26.1±1.2
Male sex — no. (%) 222 (50.8) 213 (50.8)
Born at study hospital — no. (%) 423 (96.8) 410 (97.9)
Singleton birth — no. (%) 357 (81.7) 325 (77.6)
Apgar score at 5 min‡
Median 7 7
Interquartile range 6–8 6–8
Age at randomization — hr
Median 6.7 6.6
Interquartile range 4.0–10.3 3.8–10.6
Intubated at randomization — no. (%) 301 (68.9) 287 (68.5)
Supplemental oxygen at randomization  
— no. (%)
212 (48.5) 193 (46.1)
*  Plus–minus values are means ±SD. There were no significant differences be‑
tween the treatment groups in any characteristic.
†  Race was self‑reported.
‡  Apgar scores range from 0 to 10, with higher scores indicating better function.
Table 1. Baseline Characteristics of the Mothers and Infants.*
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absence of chorioamnionitis (Fig. S3 and Table 
S5 in the Supplementary Appendix, available at 
NEJM.org).
The net treatment effect on the composite 
outcome was explained by a decrease in the in-
cidence of bronchopulmonary dysplasia. A diag-
nosis of bronchopulmonary dysplasia was made 
in 101 of the 363 infants (27.8%) assigned to 
budesonide who were alive at a postmenstrual 
age of 36 weeks, as compared with 138 of the 
363 infants (38.0%) assigned to placebo (relative 
risk, stratified according to gestational age, 
0.74; 95% CI, 0.60 to 0.91; P = 0.004). This benefit 
was offset by a nonsignificant excess in mortal-
ity with budesonide as compared with placebo 
(16.9% vs. 13.6%; relative risk, stratified accord-
ing to gestational age, 1.24; 95% CI, 0.91 to 
1.69; P = 0.17). (The survival curves are shown in 
Fig. S1 and S2 in the Supplementary Appendix.) 
No single cause of death recorded on death cer-
tificates or on autopsy reports explained the 
difference in mortality between the two groups 
(Tables S1.1 and S1.2 in the Supplementary Ap-
pendix).
Secondary Outcomes
The frequency of a patent ductus arteriosus that 
was considered by clinical staff to require surgi-
cal ligation was significantly lower among the 
infants assigned to budesonide than among 
those assigned to placebo (31 patients vs. 54 
patients; relative risk, stratified according to 
gestational age, 0.55; 95% CI, 0.36 to 0.83; 
P = 0.004), as was the frequency of the need for 
reintubation after the last administration of the 
study drug (23 patients vs. 38 patients; relative 
risk, stratified according to gestational age, 
0.58; 95% CI, 0.35 to 0.96: P = 0.03). The median 
postmenstrual age at the last use of supplemen-
tal oxygen was 31.6 weeks in the budesonide 
group and 33.1 weeks in the placebo group 
(P = 0.05) (Table 4).
The groups did not differ significantly with 
respect to the frequencies of other prespecified 
outcomes, including retinopathy of prematurity, 
brain injury, necrotizing enterocolitis, medically 
treated patent ductus arteriosus, infections, the 
occurrence of oral candidiasis requiring treat-
ment, hypertension requiring treatment or the 
occurrence of hyperglycemia requiring insulin 
treatment, days of hospitalization, increase in 
weight or head circumference, and age at the last 
use of respiratory pressure support. Rates of se-
vere adverse events were similar in the two groups 
(Table S4 in the Supplementary Appendix).
Discussion
In this multinational, randomized trial, we found 
a difference in the primary composite outcome 
— bronchopulmonary dysplasia or death — of 
borderline significance between infants ran-
domly assigned to inhaled budesonide and those 
assigned to placebo. Budesonide had disparate 
effects on the individual components of the 
composite outcome; it was associated with a 
significantly lower risk of bronchopulmonary 
dysplasia than that with placebo, which was 
offset by a nonsignificant excess in mortality.
When we designed the trial, we anticipated 
that the two components of our primary out-
come would move in the same direction. On the 
basis of a biologic rationale and the available 
clinical evidence, there was reason to hypothe-
size that inhaled glucocorticoids might reduce 
the incidence of bronchopulmonary dysplasia, but 
there was no indication that they might increase 
mortality among preterm infants. A Cochrane 
meta-analysis of five placebo-controlled trials of 
the administration of inhaled glucocorticoids 
within 2 weeks after birth showed a risk ratio 
Variable
Budesonide 
Group 
(N = 437)
Placebo 
Group 
(N = 419) P Value
Study drug
Duration of use — days† 33.9±15.9 35.6±15.4 0.07
Temporary discontinuation — no. (%) 69 (15.8) 81 (19.3) 0.17
Cointervention — no. (%)
Systemic glucocorticoids‡ 127 (29.1) 134 (32.0) 0.35
Bronchodilators 116 (26.5) 122 (29.1) 0.40
Vitamin A 62 (14.2) 49 (11.7) 0.28
Loop and other diuretics 231 (52.9) 254 (60.6) 0.02
Caffeine or other methylxanthines 414 (94.7) 398 (95.0) 0.87
*  Plus–minus values are means ±SD.
†  The use of the study drug was measured from the first to the last day of sched‑
uled administration; temporary discontinuation of study drugs and reductions 
in the dosage were not considered.
‡  Infants were considered to have received systemic glucocorticoids if they received 
at least one single dose for the prevention or treatment of bronchopulmonary 
dysplasia.
Table 2. Use of Study Drug and Cointerventions.*
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for death at 36 weeks (postmenstrual age) of 
0.73 (95% CI, 0.44 to 1.21).12 In two of the trials, 
as in our trial, glucocorticoids were adminis-
tered within 24 hours after birth21,22; in both of 
these trials, the risk ratio for death was below 1.
Our dosing regimen of budesonide was based 
largely on the Open Study of Early Corticosteroid 
Treatment, which compared early glucocorticoid 
therapy with late glucocorticoid therapy, as well 
as dexamethasone with inhaled budesonide23; 
our dose was relatively high as compared with 
that in other studies.12 However, we consider 
it unlikely that increased systemic absorption 
of the study drug could explain any differences in 
mortality. A meta-analysis of randomized trials 
of the early use of systemic postnatal glucocorti-
coids, as compared with placebo, in preterm in-
fants did not show an increased risk of mortality 
up to the time of hospital discharge (risk ratio, 
1.00; 95% CI, 0.89 to 1.13).10 The rates of death 
in our trial are consistent with those in multina-
tional randomized trials involving similar patient 
populations, including the Surfactant, Positive 
Pressure, and Oxygenation Randomized Trial24 
and the Benefits of Oxygen Saturation Targeting 
II trial.25 The difference between the rate of death 
in the budesonide group and the rate in the pla-
cebo group may be explained by chance.
Outcome
Budesonide 
Group
Placebo 
Group
Unstratified 
Relative Risk 
 (95% CI)
Stratified 
Relative Risk 
 (95% CI)† P Value
Odds Ratio 
 (95% CI)‡
no./total no. (%)
Composite primary outcome 175/437 
 (40.0)
194/419 
 (46.3)
0.86 (0.74–1.00) 0.86 (0.75–1.00) 0.05 0.71 (0.53–0.97)
Components of primary outcome
Death 74/437 
 (16.9)
57/419 
 (13.6)
1.24 (0.90–1.71) 1.24 (0.91–1.69) 0.17 1.39 (0.89–2.18)
Survival with bronchopulmonary 
dysplasia§
101/363 
 (27.8)
138/363 
 (38.0)
0.73 (0.59–0.90) 0.74 (0.60–0.91) 0.004 0.61 (0.44–0.85)
Primary outcome in subgroups
Intubated at randomization
No 29/136 
 (21.3)
48/132 
 (36.4)
0.59 (0.40–0.87) 0.61 (0.42–0.90) 0.01 0.48 (0.27–0.86)
Yes 146/301 
 (48.5)
146/287 
 (50.9)
0.95 (0.81–1.12) 0.94 (0.80–1.10) 0.45 0.84 (0.59–1.20)
Gestational age — wk
23 wk 0 days to 25 wk 6 days 104/183 
 (56.8)
109/175 
(62.3)
0.91 (0.77–1.08) 0.74 (0.48–1.15)
26 wk 0 days to 27 wk 6 days 71/254 
 (28.0)
85/244 
 (34.8)
0.80 (0.62–1.04) 0.72 (0.49–1.08)
Histologic chorioamnionitis¶
No 55/137 
 (40.1)
66/143 
 (46.2)
0.87 (0.66–1.14) 0.89 (0.68–1.16) 0.40 0.75 (0.44–1.26)
Yes 33/90 
 (36.7)
32/76 
 (42.1)
0.87 (0.60–1.27) 0.86 (0.60–1.23) 0.42 0.63 (0.31–1.28)
*  The primary outcome was a composite of death or bronchopulmonary dysplasia at 36 weeks of postmenstrual age. CI denotes confidence 
interval.
†  Stratification was performed for gestational age.
‡  Odds ratios were adjusted for the covariates of gestational age, intubation status, birth weight (<750 g vs. ≥750 g), and caffeine use with the 
use of logistic‑regression analysis; details are provided in Table S5 in the Supplementary Appendix.
§  The component of bronchopulmonary dysplasia was assessed in 363 infants in each group who were alive at a postmenstrual age of 36 weeks. 
One infant in the placebo group died 1 day after bronchopulmonary dysplasia was diagnosed.
¶  Histologic examination was performed in 446 infants (227 in the budesonide group and 219 in the placebo group).
Table 3. Primary Outcome.*
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In the Cochrane Collaboration systematic re-
view of trials of inhaled glucocorticoids admin-
istered within the first 2 weeks after birth to 
prevent chronic lung disease in preterm neo-
nates, the inclusion criteria, intervention, dose, 
and duration of therapy varied among studies, 
and none of these trials showed a significant 
reduction in the incidence of bronchopulmonary 
Outcome
Budesonide 
Group 
 (N = 437)
Placebo 
Group 
 (N = 419)
Unstratified 
 Relative Risk 
(95% CI)
Stratified 
 Relative Risk 
 (95% CI)† P Value
Retinopathy of prematurity
Stage 2 or higher — no./total no. (%)‡ 127/363 (35.0) 113/361 (31.3) 1.12 (0.91–1.38) 1.13 (0.93–1.38) 0.23
Treatment administered — no. (%) 33 (7.6) 34 (8.1) 0.93 (0.59–1.47) 0.93 (0.59–1.46) 0.75
Brain injury — no./total no. (%)§  91/428 (21.3)  70/410 (17.1) 1.25 (0.94–1.65) 1.25 (0.94–1.65) 0.12
Necrotizing enterocolitis or intestinal perforation 
— no. (%)
51 (11.7) 44 (10.5) 1.11 (0.76–1.63) 1.11 (0.76–1.61) 0.58
Necrotizing enterocolitis 29 (6.6) 33 (7.9) 0.84 (0.52–1.36) 0.84 (0.52–1.35) 0.47
Intestinal perforation 36 (8.2) 34 (8.1) 1.02 (0.65–1.59) 1.01 (0.65–1.58) 0.95
Patent ductus arteriosus — no. (%)
Treated with drugs 189 (43.2) 207 (49.4) 0.88 (0.76–1.01) 0.88 (0.76–1.01) 0.07
Treated by surgical ligation 31 (7.1) 54 (12.9) 0.55 (0.36–0.84) 0.55 (0.36–0.83) 0.004
Culture‑proven infection — no. (%)
Sepsis 148 (33.9) 125 (29.8) 1.14 (0.93–1.38) 1.13 (0.93–1.38) 0.20
Meningitis 5 (1.1) 4 (1.0) 1.20 (0.32–4.43) 1.20 (0.32–4.43) 0.79
Adverse treatment effects — no. (%)¶ 95 (21.7) 98 (23.4) 0.93 (0.73–1.19) 0.93 (0.73–1.18) 0.55
Reintubation — no. (%) 23 (5.3) 38 (9.1) 0.58 (0.35–0.96) 0.58 (0.35–0.96) 0.03
Days of hospitalization‖ 0.09
Median 91 93
Range 47–361 50–369
Change in weight from baseline to day 28 — g 274±118 278±126 0.72
Change in head circumference from baseline  
to day 28 — cm
1.6±1.2 1.4±1.4 0.21
Postmenstrual age at last use of respiratory 
 support — wk
Positive‑pressure support 0.07
Median 33.1 33.4
Interquartile range 30.7–35.4 31.4–36.3
Supplemental oxygen 0.05
Median 31.6 33.1
Interquartile range 27.9–35.4 28.3–37.1
*  Plus–minus values are means ±SD.
†  Stratification was performed according to gestational age.
‡  This outcome was assessed among infants who received retinal examinations. Of the 132 infants who did not receive a retinal examination, 
127 infants had died by the time of the examination. In the remaining 5 infants, no retinal examinations were performed.
§  This outcome was assessed among infants who underwent cranial ultrasonography. Of the 18 infants who did not undergo cranial ultraso‑
nography, all had died before the first cranial ultrasonographic examination was performed.
¶  Adverse treatment effects were defined as either oral candidiasis requiring treatment (in 28 patients in the budesonide group and 32 pa‑
tients in the placebo group), hyperglycemia requiring insulin treatment (in 86 patients in the budesonide group and 85 patients in the place‑
bo group), or hypertension requiring treatment (in 6 patients in the budesonide group and 10 patients in the placebo group).
‖  The duration of hospital stay was measured before the first discharge home.
Table 4. Secondary Outcomes.*
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dysplasia.12 We speculate that aside from our 
trial including a large enough sample size to en-
able us to detect a clinically meaningful treat-
ment effect, our positive finding with respect to 
the reduced incidence of bronchopulmonary dys-
plasia may be attributable to the early initiation 
of therapy and the choice of dose, since it has 
been shown repeatedly that only a fraction of the 
administered inhaled dose is deposited in the 
lungs.11,26,27
Budesonide was associated with a significant-
ly lower risk than the risk with placebo of two 
additional prespecified secondary outcomes — 
a patent ductus arteriosus considered by clinical 
staff to require surgical ligation and the require-
ment for reintubation after the last administration 
of the study drug. Both results could be explained 
by the effect of budesonide on the incidence of 
bronchopulmonary dysplasia. First, infants in 
whom bronchopulmonary dysplasia develops 
may have less pulmonary reserve and thus may 
be more likely to have clinical decompensation 
in the event of additional neonatal illnesses such 
as sepsis. Second, since the frequency and timing 
of echocardiography was left to the discretion of 
local clinicians, it is possible that clinical staff 
were more likely to look for and treat a patent 
ductus arteriosus in the placebo group than in 
the budesonide group, in which fewer infants 
had bronchopulmonary dysplasia. This possibil-
ity was suggested previously to explain the lower 
rates of surgical closure of a patent ductus arte-
riosus in the caffeine group than in the placebo 
group in a large randomized trial of caffeine for 
apnea of prematurity.28 Furthermore, the effect 
of budesonide on patent ductus arteriosus could 
be explained by the antiinflammatory effects of 
budesonide, which might have contributed to 
early closure of the ductus arteriosus.
The frequencies of other neonatal illnesses 
and the rate of adverse events did not differ sig-
nificantly between the groups. However, infor-
mation on short-term outcomes is insufficient to 
assess the overall efficacy of inhaled budesonide 
and its associated risks. Follow-up of our study 
cohort, including assessment of neurodevelop-
mental outcomes at 18 to 22 months of corrected 
age, is currently under way.
In summary, we found a beneficial effect of 
budesonide on the risk of bronchopulmonary 
dysplasia, as well as a possible increase in mor-
tality associated with its use.
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